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Health status and forced vital capacity (FVC) are widely used outcome measures of interstitial
lung disease (ILD) but there is a paucity of studies reporting the minimal clinically meaningful
change in these parameters. A study was undertaken to assess the minimal important differ-
ence (MID) of an ILD specific health status questionnaire, the King’s Brief ILD questionnaire
(K-BILD) and that of FVC in a range of ILDs.
57 patients with ILD (17 idiopathic pulmonary fibrosis; IPF) completed the K-BILD (score
range 0e100) at 2 separate clinic visits. Patients underwent spirometry at both visits. The
MID was determined by a range of distribution methods (Standard error of mean: SEM and03 299 4630; fax: þ44 203 299 3791.
hs.net (S.S. Birring).
3 Published by Elsevier Ltd.
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Minimal important difference in ILD 14390.3 Effect size: ES) and anchor based methods (objective: FVC and subjective: global rat-
ing of change questionnaires, GRCQ). The MID was derived by calculating an average of all
methods.
Health status was reduced at baseline in all patients, mean (SD) K-BILD total score
62(23). The average MID for K-BILD total score incorporating all methods was an 8 unit
change (range 6e10). The average MID for FVC was a 6% change of baseline (range 4e7%).
The K-BILD is a responsive patient reported outcome measure for patients with ILD. It
can potentially be used to assess patients in the clinic and evaluate the response to ther-
apy. The MID of the K-BILD total score is 8 units. The MID for FVC for a range of ILDs was
6%, similar to that reported recently for patients with IPF. Our findings will facilitate the
clinical interpretation of health status and FVC data in ILD.
ª 2013 Published by Elsevier Ltd.Introduction
Forced vital capacity (FVC), the 6 minute walk test (6MWT)
and health status are widely used outcome measures of
interstitial lung disease (ILD). Desaturation during the 6MWT
has been shown to be predictive of mortality in ILD [1].
Recent studies in idiopathic pulmonary fibrosis (IPF) have
shown that small changes in FVC are associated with clini-
cally significant changes in health status and mortality [2,3].
It is not known if small changes in FVCare clinically important
in a range of ILDs. Health status in ILD can be assessed with a
number of recently developed disease specific question-
naires [4e6]. The minimal important difference (MID) for
these tools has not been reported. The MID, defined as “the
smallest difference in score in the domain of interest which
patients perceive as beneficial and which would mandate, in
the absence of troublesome side effects and excessive cost,
a change in the patient’s (health care) management”, is
essential to facilitate meaningful clinical interpretation of
health status data [7]. The aim of this study was to investi-
gate the MID of a recently developed ILD specific health
status questionnaire, the King’s Brief Interstitial Lung Dis-
ease questionnaire (K-BILD) and also that of FVC in patients
with a range of ILDs [8]. A range of anchor and distribution
based methods were used to estimate the MIDs.
Methods
Subjects
Consecutive patients with ILD were recruited prospectively
from secondary care (King’s College Hospital) and tertiary
care (Royal Brompton Hospital) specialist clinics from
January to August 2011. Clinical characteristics, co-
morbidities and medications were recorded using a struc-
tured questionnaire. The cause of ILD was determined by a
multi-disciplinary meeting of clinicians, radiologists and
pathologists, following review of clinical characteristics,
high resolution computerised tomography (HRCT) scan, lung
function, and lung biopsy where available. The classifica-
tion of ILD was consistent with international guidelines
[9,10]. All patients gave written informed consent and the
study was approved by London-Surrey Borders research
ethics committee (ref: 09/H0806/74).Protocol
All patients completed the K-BILD at the first clinic visit and
again at a second visit greater than 4 weeks after the first,
before review with the physician each time. Forced vital
capacity (FVC) was assessed according to American
Thoracic Society standards at both visits [11]. Patients also
completed Global Rating of Change Questionnaires (GRCQ)
at the second visit. For patients undergoing a therapeutic
trial between visits, the details of treatment were
recorded.
K-BILD
The K-BILD is a self-completed health status questionnaire
that comprises of 15 items and a seven point Likert
response scale [8]. Its validation has been recently reported
[8]. It has three domains: psychological, breathlessness and
activities and chest symptoms. The K-BILD domain and total
score ranges are 0e100; 100Z best health status. A copy of
the K-BILD has been published in reference [7] and pre-
sented in Appendix (Online Supplement) [8].
Global rating of change questions (GRCQ)
The GRCQ is a 15-point scale used to determine the MID
[12]. Patients rate the change in their lung health status
between clinic visits. The response scale ranges from 7 (a
great deal worse) to þ7 (a great deal better). All subjects
were asked to complete four GRCQs, relating to K-BILD
domains and overall health status. The score for each GRCQ
was classified as unchanged (scores 1/0/1), a small
change (3, 2, 2, 3), a moderate change (5, 4, 4, 5) or
large change (7, 6, 6, 7) [12].
Minimal important difference of K-BILD
The recommended approach to estimating the MID is to use
multiple anchor-based methods with a mixture of patient
reported and clinical indicators, and to examine various
distribution-based estimates as supportive information
[13]. The MID should be representative of all these mea-
sures [13]. The K-BILD MID was estimated by both anchor-
based and distribution methods to determine a mean and
range. For the FVC anchor, subjects were categorised as
per Swigris et al., “unchanged” if the change in FVC (%)
between visits was 0e7%, “minimal change” if 7e12%,
and “more than minimal change” if greater than 12% [14].














Time since diagnosis (years) 4.0(4.4)
FVC % predicted (SD) 80(25)
TLCO % predicted (SD) 46(18)
Immunosuppressant medications at baseline (%)
None 18
Prednisolone 37
Prednisolone þ other 41
Other 4
K-BILD psychological 65(25)
Breathlessness and activities 46(28)
Chest symptoms 71(26)
Total 62(23)
All data are mean (standard deviation) unless otherwise stated.
Definitions of abbreviations: FVC Z forced vital capacity;
TLCO Z transfer factor of the lung for carbon monoxide as %
predicted; K-BILD Z King’s Brief Interstitial Lung Disease
Questionnaire.
a South Asian patients originating from the India, Pakistan or
Bangladesh.
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in K-BILD health status corresponding to a small change in
GRCQ score [7,12,15]. Two distribution-based methods
were used to estimate the MID; standard error of mea-
surement (SEM) and 0.3 effect size [13,16e18]. SEM was
calculated as standard deviation at baseline multiplied by
the square root of one minus the reliability coefficient
(Cronbach’s alpha coefficient). Effect size was calculated
by determining the mean difference in K-BILD score/stan-
dard deviation of baseline score.
Minimal important difference of FVC
The MID for FVC (%) was determined by the SEM, 0.3 ef-
fect size and the change in FVC corresponding to a small
change in GRCQ anchor.
Analysis
SPSS software, version 18 (SPSS, Chicago, IL) was used for
statistical analysis. Mean and standard deviation (SD) was
used to describe parametric data. The global rating of
change questionnaire score was expressed as an absolute
number, i.e. when the change was negative, the sign was
reversed as was the sign of the corresponding change in K-
BILD score between visits [7,12]. Correlations were
assessed with Pearsons (r) or Spearmans (r) coefficient for
non-parametric or categorical data. Paired t tests were
used for group comparisons. P < 0.05 was considered sig-
nificant. The relative change in absolute FVC was reported
as a percentage of the absolute baseline FVC.
Results
57 patients with ILD were recruited for this study (17 pa-
tients Idiopathic Pulmonary Fibrosis, 18 connective tissue
disease ILD (CTD-ILD), 9 idiopathic non-specific interstitial
pneumonia (NSIP), 8 hypersensitivity pneumonitis, 4 idio-
pathic organising pneumonia, 1 lymphoid interstitial pneu-
monia (LIP)). Demographics and baseline characteristics are
shown in Table 1. 50% of all patients (60% of IPF) had a TLCO
<40% of predicted. 16 patients underwent therapeutic tri-
als between clinic visits (4 methylprednisolone, 5 myco-
phenolate mofetil, 2 cyclophosphamide, 1 rituximab, 1
hydroxyurea, 2 N-acetylcysteine, 1 pulmonary rehabilita-
tion). The remaining patients did not undergo a change of
therapy. The mean duration between visits was 9 months.
22(38%) patients deteriorated, 14(25%) improved and
21(37%) were unchanged between visits as rated by patients
on the GRCQ scale. 21 patients reported no change in their
health status, 13 small change, 19 moderate change and 4
large change (GRCQ categories). The moderate and large
change GRCQ categories were combined for further analysis
since the large change group contained a small numbers of
patients (n Z 4). Health status was reduced in all domains
at baseline (Table 1). The K-BILD was a responsive instru-
ment in those patients indicating a change in their health.
There was a significant change in K-BILD total score from
visit 1e2 in patients reporting a change in GRCQ; mean (SD)
62(21) vs. 50(19); mean difference 12; 95% confidence in-
terval of difference 6 to 18; p < 0.01. The anchors used in
this study were significantly related to changes in healthstatus. There was a significant correlation between GRCQ
and change in K-BILD (r Z 0.52, p < 0.01; Fig. 3 Online
Supplement) and between change in FVC and change in K
BILD (r Z 0.41, p < 0.01; Fig. 4 Online Supplement). The
change in health status scores for each GRCQ category is
given in Table 2. There were no significant differences in
change in FVC or K-BILD scores between never smokers and
current/ex-smokers (p Z 0.40e0.96). The K-BILD total
score MID corresponding to the FVC anchor was 10, GRCQ
anchor: 8, 1 SEM: 6 and 0.3 ES: 7 (Table 2 and Fig. 1). The
mean (range) MID for K-BILD total score was 8(6e10). The
change in K-BILD total score for patients in the GRCQ MID
category was; mean (SD) before 61(22) vs. after 53(15);
mean difference 8; 95% confidence interval of difference
0 to 17; pZ 0.059. The change in K-BILD score for each FVC
category is shown in Fig. 2.
The mean (SD) change in FVC (visits 1e2) for each GRCQ
category was: no change 2.6(8.1)%, small change (MID)
4.4(14.4)% and moderate-large change 15.1(22.0)%. The
MIDs for FVC using GRCQ anchor method was 4%, 1 SEM
method: 7% and 0.3 ES method: 7%. The mean (range) MID
for FVC from all methods was 6(4e7)%. The mean (SD) FVC
when calculated as an absolute change in % of predicted
values for patients reporting no change and minimal change
from visits 1e2 was 0.5(6.5)% and 2.2(10.3)% respectively.
Table 2 Minimal important difference of K-BILD.
GRCQ change FVC change 1 SEM ES 0.3
Same Minimal important
difference
Moderateelarge FVC 0e7% FVC 7e12% FVC >12%
K-BILD psychological 6.6(9.0) 9.5(18.1) 21.8(21.3) 1.5 9.9(8.6) 20.0 7.6 7.4
K-BILD breathlessness
and activities
5.2(7.6) 11.3(17.6) 15.2(23.0) 2.5 4.3(6.4) 13.9 10.1 8.5
K-BILD chest 7.2(19.9) 11.5(19.9) 16.2(18.6) 2.0 18.4(21.5) 7.1 13.7 7.9
K-BILD total 0.80(11.9) 8.2(14.1) 14.5(18.4) 1.3 10.1(6.8) 16.4 5.8 7.0
All data are mean (standard deviation). Positive and negative changes in each GRCQ and FVC category are grouped together. Definitions
of abbreviations: GRCQZ global rating of change questionnaire; VCZ vital capacity; SEMZ standard error of baseline measurement;
ES Z effect size; K-BILD Z King’s Brief Interstitial Lung Disease Questionnaire.
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This is the first study to report the MID of FVC and ILD
specific health status in a wide range of ILDs. The MID for
FVC was a small change, 6% of baseline. The MID for K-BILD
total score determined by a range of anchor and distribu-
tion methods was 6e10 units, average 8 units. Our study
suggests that both FVC and health status questionnaires are
responsive outcome measures and that they can be used to
assess patients with ILD in the clinic.
We investigated the MID for K-BILD domain and total
scores with a range of anchor and distribution methods. The
MID range for total score was 6e10 units. The pre-specified
method of determining the MID was an average of all
methods, 8 units. We chose this in preference to any single
method since it encompassed both the patients’ perspective
and objective assessments. No single method of determining
the MID has consensus opinion, however there is consensus
that multiple methods and anchors should be used [13]. The
GRCQ anchor method has been used by some investigators to
determine the MID [12,19]. The GRCQ MID was within close
approximation to that determined by other methods.Figure 1 Change in K-BILD health status scores per global
rating of change category. All data are mean (standard error
mean: SEM). Definitions of abbreviations: K-BILDZ King’s Brief
Interstitial Lung Disease Questionnaire.The GRCQ was significantly associated with change in K-BILD
scores. The change in health status of patients reporting
minimal change (GRCQ) approached statistical significance.
A significant limitation of patient reported anchors such as
GRCQ or SF36 (Du Bois et al.) is recall bias [3]. They are more
likely to reflect current health status than change from a
previous clinic visit [20]. The average time between assess-
ments in our studywas long, 9months, similar to the study by
Du Bois et al. (11 months) making recall bias a possibility [3].
However, FVC-anchor and distribution methods for deter-
mining the MID were not subject to recall bias. Further
studies should utilise prospective patient rated scales that
assess change, such as the Punum ladder, to eliminate recall
bias [20]. It is possible that the FVC anchor method (7e12%
change) overestimated the MID for K-BILD total score (10)
since this change in FVC is larger than the MID for FVC
determined in our study. We chose a 7e12% change in FVC as
minimally important to be consistent with previous studies
reporting the MID [14,21].
Swigris et al. investigated the MID of health status in IPF,
assessed with St Georges Respiratory Questionnaire (SGRQ;Figure 2 The relationship between longitudinal changes in
forced vital capacity and health status. All data are mean
(standard error mean: SEM). Definitions of abbreviations:
K-BILD Z King’s Brief Interstitial Lung Disease Questionnaire.
1442 A.S. Patel et al.original version) and Short form 36 (SF36) [14]. There were
key differences between their study and ours. The SF36 and
SGRQ are generic health and respiratory questionnaires
respectively and the anchor used was a breathlessness scale
(Transition Dyspnea Scale). The TDI focuses on a single
symptom; it is not known if this impacts its ability to cap-
ture the wider change in a patients’ lung health. There are
two other ILD specific health status questionnaires, a tool
to assess quality of life-IPF (ATAQ-IPF) and SGRQ-IPF; their
MID has not been reported [4,5].
There is a paucity of studies that have investigated the
MID of FVC despite this being a widely used outcome
measure of ILD. The MID of FVC has largely been evaluated
against mortality in the past and a change of 10% is often
considered significant [10,22,23]. Death cannot be charac-
terised as minimally important and therefore estimates
based on this approach may not appropriately reflect the
smallest difference that is clinically important to patients
[3]. A MID for FVC determined by the progression of disease
based on symptoms is an alternative approach. We are
aware of only one other study that has investigated the MID
of FVC using a patient reported anchor of change [3]. Du
Bois et al. investigated the MID of predicted FVC (%) in 363
patients with IPF over a 48 week interval. An item from the
SF36 questionnaire that assesses change in general health
over the previous year was used as the anchor. The MID
using this patient rated anchor method was a change in FVC
% predicted of 2.3%, similar to our finding (2.2% percent
predicted or 4.4% relative change in absolute FVC; GRCQ
method). The strength of the Du Bois study was its large
size and fixed timings of assessments in a clinical trial
setting. However, there were limitations with this study.
The patient rated anchor was not lung specific; changes in
non-pulmonary health during the study period may have
influenced the patients’ response to the anchor question.
The Du Bois study excluded patients with severe ILD, a
clinically important subgroup and therefore their findings
cannot be generalised to this population. Lastly, the FVC
MID determined by the patient anchor approach was less
than the change observed in patients reporting no change in
health (2.3% vs. 2.8%). The reasons for this are unclear. Our
study has addressed some of these limitations. We evalu-
ated the MID using a lung specific patient anchor. We
included patients with a wide range of disease severity. A
significant proportion of patients, particularly those with
IPF had severe lung disease. The MID in our study was
distinct from the change in FVC observed in patients who
indicated their health was unchanged. Our study is consis-
tent with Du Bois et al. that a small change in FVC is
important to patients and suggests this is applicable across
a wide range of ILDs and disease severity [3]. The MID
determined by a symptom based anchor is considerably
smaller than that anchored with mortality. The MID how-
ever is likely to be higher for individual patients compared
to that of a population and hence should be interpreted
with caution in this respect.
There are limitations to this study. A small sample size
was a key limitation and only 4 subjects were recruited in
the “large change” category; our findings need to be
confirmed in a larger study, with longer duration of follow-
up and preferably with a single well defined intervention. It
is possible that the MID for more severe and rapidlyprogressive ILDs such as IPF may differ to other ILDs. We
were unable to determine single ILD category MIDs due to
the small sample size. IPF was the largest single category in
our study. It is not known if the responsiveness of the K-BILD
differs between categories of ILD but we have previously
reported that the construct and concurrent validity is
similar in IPF to other ILDs [8]. Our study included patients
who were observed between clinic visits as well as those
undergoing a trial of therapy. It is possible this may have
affected the estimation of MID. Our approach reflected real
life practice; a standardised approach is needed in future
studies. This is more achievable in a large multi-centre
clinical trial. We were unable to determine separate MIDs
for patients whose health improved and deteriorated, due
to our small sample size. The change in the K-BILD chest
domain was smaller in the FVC change >12% group
compared to FVC change 7e12%. The reason for this is
unclear. The chest domain focussed on symptoms other
than breathlessness. One possibility is that interventions
impacting breathlessness may not have had a similar impact
on chest symptoms such as chest tightness and air hunger.
In conclusion, the data from this study suggests that MID
for FVC may be similar for a range of ILDs that include IPF.
We confirm previous findings that a small change in FVC is
perceived to be important by patients. Our study also
suggests the K-BILD is a responsive health status outcome
measure in ILD and the MID is a score of 8 units. The K-BILD
may be useful in the assessment of the efficacy of therapy.
This study should facilitate the clinical interpretation of
health status and FVC outcome measures in ILD.Conflict of interest statement
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